Tefferi A, Barbui T. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1465–87.

Article  PubMed  CAS  Google Scholar 

Griesshammer M, Sadjadian PT. BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Expert Opin Pharmacother. 2017;18:1929–38.

Article  PubMed  CAS  Google Scholar 

Kralovics R, Passamonti F, Buser AS, Teo S‑S, Tiedt R, Passweg JR, et al. A Gain-of-Function Mutation of JAK 2 in Myeloproliferative Disorders. N Engl J Med. 2005;352:1779–90.

Article  PubMed  CAS  Google Scholar 

James C, Ugo V, Le Couédic J‑P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK 2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–8.

Article  PubMed  CAS  Google Scholar 

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK 2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.

Article  PubMed  CAS  Google Scholar 

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK 2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. N Engl J Med. 2007;356:459–68.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK 2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.

Article  PubMed  CAS  Google Scholar 

Lee T‑S, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK 2 exons 13–15: comparison with V617F and exon 12 mutations. BMC Struct Biol. 2009;9:58.

Article  PubMed  PubMed Central  Google Scholar 

Duminuco A, Harrington P, Harrison C, Curto-Garcia N. Polycythemia Vera: Barriers to and Strategies for Optimal Management. Blood Lymphat Cancer. 2023;13:77–90.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Moliterno AR, Kaizer H, Reeves BN. JAK 2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Regimbeau M, Mary R, Hermetet F, Girodon F. Genetic Background of Polycythemia Vera. Genes (basel). 2022;13:637.

Article  PubMed  CAS  Google Scholar 

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299–307.

Article  PubMed  CAS  Google Scholar 

Passamonti F, Rumi E, Pietra D, Porta MGD, Boveri E, Pascutto C, et al. Relation between JAK 2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676–82.

Article  PubMed  CAS  Google Scholar 

Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21–30.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21:1952–9.

Article  PubMed  CAS  Google Scholar 

Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–13.

Article  PubMed  CAS  Google Scholar 

Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK 2 exon 12 in patients with JAK 2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686–9.

Article  PubMed  CAS  Google Scholar 

Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK 2 exon 12 mutations. Blood. 2011;117:2813–6.

Article  PubMed  CAS  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H‑M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140:2228–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Loscocco GG, Coltro G, Guglielmelli P, Vannucchi AM. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms. Cells. 2021;10:1962.

Article  PubMed  PubMed Central  Google Scholar 

Guglielmelli P, Pietra D, Pane F, Pancrazzi A, Cazzola M, Vannucchi AM, et al. Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders—A consensus project of the Italian Society of Hematology. Leuk Res. 2017;58:63–72.

Article  PubMed  Google Scholar 

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK 2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia. 2013;27:2032–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gong JZ, Cook JR, Greiner TC, Hedvat C, Hill CE, Lim MS, et al. Laboratory Practice Guidelines for Detecting and Reporting JAK 2 and MPL Mutations in Myeloproliferative Neoplasms. J Mol Diagnostics. 2013;15:733–44.

Article  CAS  Google Scholar 

Rai S, Zhang Y, Grockowiak E, Kimmerlin Q, Hansen N, Stoll CB, et al. IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK 2-mutant hematopoietic stem cells. Blood Adv. 2024.

Google Scholar 

Van Egeren D, Escabi J, Nguyen M, Liu S, Reilly CR, Patel S, et al. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021;28:514–523:e9.

Google Scholar 

Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602:162–8.

Article  PubMed  CAS  Google Scholar 

Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018;16:360.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK 2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960–3.

Article  PubMed  CAS  Google Scholar 

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

Article  PubMed  PubMed Central  Google Scholar